Ultragenyx Pharma (RARE) Misses Q2 EPS by 20c

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.83), $0.20 worse than the analyst estimate of ($0.63).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
• Netskope, Inc. (NTSK) Tops Q2 EPS by 4c, Offers Guidance
• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance